Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Results come after positive results from a trial among people with idiopathic pulmomary disease.

A panelist discusses how the POD1UM-303 randomized phase 3 trial demonstrated that adding retifanlimab (a PD-1 inhibitor) to ...

A panelist discusses how the most effective therapy for squamous cell anal carcinoma is prevention through human ...

The healthcare provisions include Medicaid work requirements and a broadening of the exemption to Medicare drug price negotiation ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

An investigational oral targeted therapy, zipalertinib (CLN-081), demonstrated meaningful tumor responses and a manageable ...

In an opinion article, investigators argue that gene therapies may not achieve their full potential if the innate inflammation in Duchenne muscular dystrophy is not effectively managed.

According to Regeneron, the drug is a bispecific antibody that binds to B-cell maturation antigen (BCMA) on cancerous plasma cells and CD3 on T cells, directing the immune system to attack and destroy ...

In a conversation with Managed Healthcare Executive, Michael Abrams, M.A., managing partner at Numerof & Associates, painted ...

While the impact of Medicaid changes on employer-sponsored insurance remains to be seen, competition between providers is a ...